Clinical trials: IgAN - IgA Nephropathy
Glomerulonephritis
Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor
To evaluate the efficacy of the ACE inhibitor ramipril in the treatment of early IgA nephropathy.
- Trial name
- NCT00437463
- Testing
- Ramipril
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Sanofi
IGA Nephropathy
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
Phase 2, multi-center, open label extension study to evaluate 2 dose regimens of fostamatinib in approximately 25 subjects. The study will consist of 11 visits over 15 months.
- Trial name
- NCT02433236
- Testing
- Fostamatinib Disodium tablet 100 mg, Fostamatinib Disodium tablet 150 mg
- Sponsor
- Rigel Pharmaceuticals
IgA Nephropathy
Study of BHV-1400 in IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
- Trial name
- NCT07054684
- Testing
- BHV-1400
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Biohaven Therapeutics Ltd.
Immunoglobulin A Nephropathy, Glomerular Disease
Safety and Efficacy Study of VIS649 for IgA Nephropathy
The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
- Conditions
- Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
- Trial name
- NCT04287985
- Testing
- Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
- Where
- 93 sites in United States, Australia and 13 more
- Volunteers
- 155 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Biopsy-confirmed IgA Nephropathy, Proteinuria Less Than 0.5 g Per Day
Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial
Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. The treatment of IgA nephropathy with normal renal function and minimal proteinuria is unknown.
- Conditions
- Biopsy-confirmed IgA Nephropathy, Proteinuria Less Than 0.5 g Per Day, Normal Blood Pressure, Serum Creatinine Below 120 Umol/l
- Trial name
- NCT01225445
- Testing
- Ramipril
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Primary IgA-nephropathy, High-risk
Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy
The open-label prospective non-randomised controlled aims to assess the efficacy of the combination of immunosupression (IST) and tonsillectomy (TE) in Caucasian patients at high risk of the IgA-nephropathy.
- Conditions
- Primary IgA-nephropathy, High-risk, Caucasians
- Trial name
- NCT07074951
- Testing
- Immunosuppressive treatment, Tonsillectomy
- Where
- 2 sites in Russia
- Volunteers
- 240 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Autoimmune Diseases, SLE - Systemic Lupus Erythematosus
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
This is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a universal CD19/BCMA dual-targeting chimeric antigen receptor T-cell…
- Conditions
- Autoimmune Diseases, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies
- Trial name
- NCT07674147
- Testing
- RD06-05 CART Cell Infusion
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Primary IgA Nephropathy
A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
This study aims to evaluate the long-term safety of HRS-5965 capsules in patients with primary IgA nephropathy, and also to assess its efficacy in reducing 24-hour urinary protein and delaying the decline in eGFR in these…
- Trial name
- NCT07582133
- Testing
- HRS-5965 Capsules
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Berger Disease, Bergers Disease
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to <18 years with primary immunoglobulin A nephropathy (IgAN).
- Conditions
- Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
- Trial name
- ADVANCE (NCT07498335)
- Testing
- Drug: Atrasentan
- Where
- 18 sites in United States, China and 5 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
pMN, IgAN
Atacicept in Multiple Glomerular Diseases
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
- Conditions
- pMN, IgAN, Nephrotic Syndrome, MCD
- Trial name
- NCT06983028
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Vera Therapeutics, Inc.
IgA Glomerulonephritis
Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
This multicenter, open-label, prospective single-arm study will enroll adults (≥18 y) with primary IgA nephropathy confirmed by renal biopsy within 2 weeks, eGFR ≥20 ml/min/1.73 m² and 0.5-3.5 g/d proteinuria, to receive early…
- Trial name
- NCT07585981
- Testing
- NEFECON
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Primary Immunoglobulin a Nephropathy (IgAN)
Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in Chinese patients who have completed Nef-301 and continue to be treated with a stable dose of…
- Trial name
- NCT05534919
- Testing
- Nefecon
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Everest Medicines (Singapore) Pte. Ltd.
IgA Nephropathy
A Study of Probiotics in IgA Nephropathy
IgA nephropathy (IgAN) occurs when a specific form of the IgA antibody lodges on the kidneys and causes damage, which may lead to kidney failure. This form of IgA is likely to come from the gut and the upper airways.
- Trial name
- Pro-IgAN (NCT06767592)
- Testing
- Bio-Kult Advanced
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- University of Leicester
Immunoglobulin A Nephropathy
A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)
In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). IgAN is a kidney disease caused by the buildup of an antibody called IgA in the kidneys over time.
- Trial name
- NCT07889362
- Testing
- Felzartamab
- Volunteers
- 25 people
- Sponsor
- Biogen
Glomerulonephritis, IGA
Study of the IgA Repertoire During IgA Deposition Nephropathy.
IgA plays a major role in mucosal and systemic immunity but retains mysterious and ambivalent aspects. They can thus, depending on the situation, prove to be capable of triggering either a protective inflammatory response or, on…
- Trial name
- ERINA (NCT04092491)
- Testing
- blood sample
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
IgA Nephropathy
A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients
This study is to evaluate efficacy and safety of tacrolimus in the patients with non-nephrotic albuminuric, normotensive IgA nephropathy after 16 week treatment with tacrolimus (Prograf) or placebo.
- Trial name
- NCT01224028
- Testing
- Tacrolimus
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Astellas Pharma Inc
IgA Nephropathy
Rituximab and RASi in Patients with IgAN
A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.
- Trial name
- RITA (NCT04525729)
- Testing
- Rituximab, RAS 2410
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Nan Chen,MD
IgA Nephropathy
Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study
immunoglobulin A (IgA) nephropathy (Berger disease) is the most frequent primary glomerulonephritis worldwide. This disease accounts for about 5% of the causes of end stage renal disease in France, representing a major public…
- Trial name
- QUIgAN (NCT06350630)
- Testing
- Hydroxychloroquine Oral Tablet
- Where
- 8 sites in France
- Volunteers
- 334 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Glomerular Disease
Vitamin D Supplementation in Glomerular Disease
This multi-site, pilot study will assess vitamin D supplementation in children and young adults with Glomerular Disease. .
- Trial name
- NCT01835639
- Testing
- Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Children's Hospital of Philadelphia
Glomerulonephritis, IGA, Peripapillary Crescent
A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.
This prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of steroids therapy for patients of IgA nephropathy with active pathological changes,including crescents,necrosis and…
- Conditions
- Glomerulonephritis, IGA, Peripapillary Crescent, Necrosis, Steroid Nephropathy
- Trial name
- NCT02160132
- Testing
- Methylprednisolone(intravenously in the 1st-2nd-3rd month ), Methylprednisolone(intravenously in the 1st-3rd-5th month)
- Where
- 6 sites in China
- Volunteers
- 180 people
- Sponsor
- Sun Yat-sen University